Clinical trials: IBD
Ulcerative Colitis
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
- Trial name
- SEA TURTLE (NCT04577794)
- Testing
- GLPG3970
- Where
- 15 sites in Georgia, Moldova and 2 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn's Disease
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease…
- Trial name
- NCT01258205
- Testing
- AMG 139
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Crohn Disease
A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials
The main objectives of this study are to evaluate the long-term safety of spesolimab in patients with perianal fistulising Crohn's disease who have completed treatment in parent trials and to evaluate the long-term efficacy of…
- Trial name
- NCT04362254
- Testing
- Spesolimab
- Where
- 7 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Inflammatory Bowel Diseases
A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease
The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with…
- Trial name
- GO-ON (NCT07822529)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
- Trial name
- NCT02958865
- Testing
- PF-06700841, PF-06651600
- Where
- 189 sites in United States, Austria and 17 more
- Volunteers
- 319 people
- Sponsor
- Pfizer
Irritable Bowel Syndrome With Diarrhea
Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1
This study was conducted to investigate the effects of daily supplementation of L. plantarum APsulloc 331261(GTB1TM) on improvement of IBS symptoms.
- Trial name
- NCT05277428
- Testing
- GTB1
- Where
- South Korea
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Amorepacific Corporation
Ulcerative Colitis (UC), Severe Ulcerative Colitis
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body…
- Conditions
- Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
- Trial name
- ASCENTRA-UC (NCT07845487)
- Testing
- PALI-2108
- Where
- 115 sites in United States, Canada and 10 more
- Volunteers
- 204 people
- Sponsor
- Palisade Bio
Crohn Disease
An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease
The purpose of this program is to provide early access to ustekinumab where it is commercially unavailable for the treatment of participants with moderately to severely active Crohn's disease who have failed treatment with…
- Trial name
- NCT03362736
- Testing
- Ustekinumab
- Where
- 6 sites in Brazil
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
The purpose of this study is to determine the safety and pharmacokinetics of MMX mesalamine following administration in children and adolescents with ulcerative colitis.
- Trial name
- NCT01130844
- Testing
- MMX Mesalamine
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 52 people
- Sponsor
- Shire
Crohn's Disease
A Study of Vedolizumab in Adults With Crohn's Disease (CD)
The main aim of this study is to see if adults with CD treated with vedolizumab have less symptoms and inflammation of the bowel assessed by ultrasonography.
- Trial name
- SUNRISE (NCT05192863)
- Testing
- No Intervention
- Where
- 10 sites in Canada, Israel and 1 more
- Volunteers
- 72 people
- Sponsor
- Takeda
Ulcerative Colitis
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy
The objective of this study is to evaluate the efficacy and the tolerability of oral parnaparin sodium (210mg), administered in extended-release tablets identified as CB-01-05-MMX™.
- Trial name
- NCT00867438
- Testing
- Sigmoidoscopy
- Volunteers
- 133 people
- Sponsor
- Cosmo Technologies Ltd
IBS (Irritable Bowel Syndrome)
A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS).
- Trial name
- NCT07540312
- Testing
- Variable Compression System
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- PGP Health
Ulcerative Colitis, Ulcerative Proctitis
A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis
This will be a phase I/IIa, open-label, three-stage, single center study aimed at investigating the safety, the efficacy (clinical and endoscopic effects) and the pharmacokinetics of Niclosamide enema 150 mg/60 ml and 450 mg/60…
- Conditions
- Ulcerative Colitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
- Trial name
- NCT03521232
- Testing
- Niclosamide
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Entero Therapeutics
Crohns Disease
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
The study is being conducted to evaluate the pharmacokinetic parameters (Cmax, Tmax and AUC) of the new delayed release, lowered dose, 40 mg 6MP test formulation as compared to standard 6MP (100 mg Purinethol) in 12 patients with…
- Trial name
- NCT00774982
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Teva GTC
Ulcerative Colitis
Open-label Extension Study of Brazikumab in Ulcerative Colitis
The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term…
- Trial name
- Expedition (NCT04277546)
- Testing
- Brazikumab Maintenance Dose, Brazikumab Induction Dose
- Where
- 36 sites in United States, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Crohn's Disease
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive…
- Trial name
- DIVERSITY1 (NCT02914561)
- Testing
- Filgotinib
- Where
- 513 sites in United States, Argentina and 39 more
- Volunteers
- 1,372 people
- Sponsor
- Lakefront Biotherapeutics NV
Ulcerative Colitis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis
To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)
- Trial name
- NCT01164904
- Testing
- Amg 181
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Amgen
Crohn Disease
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
The purpose of study is to test the effects of an experimental medication GED-0301 (mongersen) in patients who have active Crohn's disease. The study will test GED-0301 compared to placebo for 52 weeks.
- Trial name
- NCT02596893
- Testing
- GED-0301
- Where
- 538 sites in United States, Australia and 33 more
- Volunteers
- 701 people
- Sponsor
- Celgene
Colitis, Ulcerative, Crohn Disease
A Study of Vedolizumab in Adults in Real-World Practice
Vedolizumab is a medicine that is currently prescribed for adults with moderately to severely active ulcerative colitis or Crohn's disease.
- Trial name
- NCT04872491
- Where
- 40 sites in China
- Volunteers
- 500 people
- Sponsor
- Takeda
Pouchitis
Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis
Phase 2 Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis
- Trial name
- FILLMORE (NCT04741087)
- Testing
- AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B
- Where
- 34 sites in United States, Belgium and 8 more
- Volunteers
- 22 people
- Sponsor
- Applied Molecular Transport